Navigating the landscape of pharmaceutical excipients is a masterclass in balancing scientific ambition with stringent regulatory realities. When industry discussions turn to innovation, the term “new excipient” is often thrown around loosely, but its practical definition is far more nuanced. As David Schoneker, president of Black Diamond Regulatory Consulting, points out, new excipients encompass everything from novel chemical entities (NCEs) and higher usage levels to new routes of administration, specialized patient populations, co-processed materials, and functional adaptations from the food and cosmetics industries.
Yet, despite this broad spectrum of potential, the adoption of new excipients by formulators is notoriously slow. True novel NCE excipients remain exceptionally rare, primarily due to the prohibitive volume of safety data required for regulatory approval. The pharmaceutical industry is inherently risk-averse, rarely embracing a novel material unless it provides an absolute solution to a formulation challenge that no existing substance can solve. While small-molecule drugs continue to drive the bulk of new development due to high market uptake, large molecule commercialization occasionally hinges entirely on pioneering a novel excipient, sparking rare, highly collaborative partnerships between excipient manufacturers and pharma developers.